DK2820008T3 - Amido-spirocycliske amid- og sulfonamidderivativer - Google Patents

Amido-spirocycliske amid- og sulfonamidderivativer Download PDF

Info

Publication number
DK2820008T3
DK2820008T3 DK13755811.0T DK13755811T DK2820008T3 DK 2820008 T3 DK2820008 T3 DK 2820008T3 DK 13755811 T DK13755811 T DK 13755811T DK 2820008 T3 DK2820008 T3 DK 2820008T3
Authority
DK
Denmark
Prior art keywords
alkyl
mmol
equiv
methyl
cancer
Prior art date
Application number
DK13755811.0T
Other languages
English (en)
Inventor
Kenneth W Bair
Timm R Baumeister
Peter DRAGOVICH
Xiongcai Liu
Snahel Patel
Mark Zak
Guiling Zhao
Yamin Zhang
Xiaozhang Zheng
Original Assignee
Genentech Inc
Forma Tm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Forma Tm Llc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK2820008T3 publication Critical patent/DK2820008T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (15)

  1. AMIDO-SPIROCYCLISKE AMID- OG SULFONAMIDDERIVATIVER
    1. Forbindelse med formlen I: hvori:
    R er (a) en 8-, 9- eller 10-leddet bicyklisk heteroaryl omfattende ét heteroatom udvalgt fra N, S og O og et, to eller tre yderligere N-atomer, hvori den bicycliske heteroaryl er ikke-substitueret eller er substitueret med en eller flere substituenter udvalgt fra gruppen bestående af deuterium, amino, alkylamino, dialkylamino, alkyl, halo, cyano, haloalkyl, hydroxy, hydroxyalkyl og alkoxy, og hvori et eller flere af den bicycliske heteroaryls N-atomer eventuelt er N-oxid; eller (b) en fem- eller seksleddet nitrogen-koblet heterocycloalkyl-ring kondenseret til en phenyl- eller monocyklisk fem- eller seksleddet heteroaryl, hvori phenylen er ikke-substitueret eller er substitueret med en eller flere substituenter udvalgt fra gruppen bestående af deuterium, amino, alkylamino, dialkylamino, alkyl, halo, cyano, haloalkyl, hydroxy, hydroxyalkyl og alkoxy; og RI er H, -(Cl-4alkylen)0-1C(0)Ra, -(Cl-4alkylen)0-lCO2Ra, -(Cl-4alkylen)O-IS(0)Ra, -(Cl-4alkylen)0-lSO2Ra, -C(0)NH(Ra),-C(0)N(Ra)2 eller -C(0)C(0)NH(Ra) ; hvori hver Ra uafhængigt er (1) alkyl, ikke-substitueret eller substitueret med en eller flere Rm -substituenter, hvori hver Rm er uafhængigt udvalgt fra gruppen bestående af hydroxy, - NRbRc, alkoxy, cyano, halo, -C(O)alkyl, - C02alkyl, -CONRbRc, -S(O)alkyl, -S02alkyl, -S02NRbRc, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, phenoxy og -O-alkyl-OH; hvori Rb er H eller alkyl; Rc er H, alkyl, alkoxyalkyl, haloalkyl, -C(0)alkyl, -C02alkyl, -S02alkyl, -C(0)NH2 eller C(0)H; og hver aryl-, heteroaryl-, cycloalkyl- og heterocycloalkyl-gruppe inden for Rm er ikke-substitueret eller substitueret med en eller flere substituenter uafhængigt udvalgt fra gruppen bestående af alkyl, haloalkyl, hydroxy, -NRbRc, alkoxy, haloalkoxy, cyano, halo, oxo, -C(0)alkyl, -C02alkyl, -C(0)-heterocycloalkyl, -CONRbRc, -S(0)alkyl, -S02alkyl, -S02-haloalkyl, - S02NRbRc, aryl, heteroaryl, cycloalkyl og heterocycloalkyl; hvori hver alkyl eller alkoxy er ikke-substitueret eller substitueret med -NRbRc, heterocycloalkyl, heteroaryl eller -C(0)alkyl; og hver aryl, heteroaryl, cycloalkyl og heterocycloalkyl er ikke-substitueret eller er substitueret med alkyl, halo eller -C(O)alkyl; (2) phenyl, cycloalkyl, heteroaryl eller heterocycloalkyl, hver ikke-substitueret eller substitueret med en eller flere substituenter udvalgt fra gruppen bestående af alkyl, haloalkyl, hydroxy, -NRbRc, alkoxy, haloalkoxy, cyano, halo, oxo,-C(0)alkyl, -C02alkyl, -C(0)-heterocycloalkyl, -CONRbRc, -S(0)alkyl, -S02alkyl, -S02-haloalkyl, -S02NRbRc, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl; hvori hver alkyl eller alkoxy er ikke-substitueret eller substitueret med -NRbRc, heterocycloalkyl, heteroaryl eller -C(O)alkyl; og hver aryl, heteroaryl, cycloalkyl og heterocycloalkyl er ikke-substitueret eller substitueret med alkyl, halo eller -C(0)alkyl; eller (3) -NkxRy, hvor Rx er H eller alkyl; og Ry er H, alkyl, alkoxyalkyl, haloalkyl, -C(0)alkyl, -C02alkyl eller -S02alkyl; R2 og R3 hver uafhængigt er H eller deuterium; og n er 1 eller 2; eller en stereoisomer deraf eller et farmaceutisk acceptabelt salt af en sådan forbindelse eller stereoisomer.
  2. 2. Forbindelse ifølge krav 1, hvori R er en 8- eller 9-leddet heteroaryl, ikke-substitueret eller substitueret som beskrevet i krav 1.
  3. 3. Forbindelse ifølge krav 1 eller 2, hvori R er:
    c hver ikke-substitueret eller substitueret som beskrevet for krav 1.
  4. 4. Forbindelse ifølge krav 1, hvori R er en fem- eller seksleddet nitrogen-koblet heterocycloalkyl-ring kondenseret til en ikke-substitueret eller substitueret phenyl- eller monocyklisk heteroaryl, som defineret i krav 1.
  5. 5. Forbindelse ifølge krav 1, hvori Ri er H, -C(0)Ra, -C02Ra, -S(0)Ra eller -S02Ra.
  6. 6. Forbindelse ifølge et hvilket som helst af kravene 1 til 5,hvori Ra er methyl, ethyl, propyl, isopropyl, tert-butyl, isobutyl, isopentyl, phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolyl, furanyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, triazoyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, isoindolinyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, tetrahydrofuranyl, tetrahydropyranyl eller tetrahydrothiophenyl, hver ikke-substitueret eller substitueret.
  7. 7. Forbindelse ifølge et hvilket som helst af kravene 1 til 6, hvori Ra er phenyl, cycloalkyl, heteroaryl eller heterocycloalkyl, hver ikke-substitueret eller substitueret med en eller flere substituenter udvalgt fra gruppen bestående af fluor, oxo, methyl, -C0NH2, acetyl, -S02methyl, -C(0)-isopropyl, pyridazinyl, triazolyl, dimethylaminomethyl, cyano, methyl-triazolylmethoxy, trifluormethoxy, pyrrolidinylmethyl, acetylamino, tetrazolylmethyl, methyl-tetrazolylmethyl, methyl-imidazolyl-methyl, -NHS02methyl, 1,1-dioxothiomorpholinyl, 4-methyl-piperazinylmethyl, -NHC0NH2, -S02CF3, morpholinylmethyl, imidazolyl, -S02NH2, methylpiperidinyl, methyl-piperazinyl, -C(0)(4-methyl-piperazinyl), morpholinyl, trifluormethyl, cyclopropyl, ethyl, isoxazolyl, tetrazolyl, isopropyl, phenyl, fluor-phenyl, tert-butyl, benzyl, Nmethylpyrrolidinyl, N-acetyl-pyrrolidinyl, isobutyl, propyl, methylpyrazolyl, trifluorethyl, pyrimidinyl, oxo, acetyl, cyano, -C02-tert-butyl og amino.
  8. 8. Forbindelse ifølge et hvilket som helst af kravene 1 til 6, hvori Ra er alkyl, ikke-substitueret eller substitueret med en eller flere substituenter udvalgt fra gruppen bestående af fluor, tert-butoxy, -C(0)NMe2, -NHCHO, methoxy, phenoxy, cyano, acetyl, hydroxy, -0CH2C(CH3)=0H,-NH(acetyl) og -N(Me)(acetyl).
  9. 9. Forbindelse ifølge krav 1, hvori RI er -S02Ra, hvor Ra er methyl, ethyl, phenyl, benzyl eller 2,2-dimethylpropyl.
  10. 10. Forbindelse ifølge krav 1, hvori RI er -C(0)NHRa, hvori Ra er methyl, ethyl, propyl, isopropyl, tertobutyl, cyclohexyl, -CH2-cyclohexyl, oxetanyl eller methyloxetanyl, eller Ra er en phenyl- eller benzyl-gruppe, hver eventuelt substitueret med en eller flere substituenter udvalgt fra gruppen bestående af cyano, methyl, fluor, methoxy og chlor.
  11. 11. Forbindelse ifølge krav 1, der er udvalgt fra gruppen bestående af:
    og stereoisomerer deraf og farmaceutisk acceptable salte af sådanne forbindelser og stereoisomerer.
  12. 12. Farmaceutisk sammensætning omfattende: (a) en effektiv mængde af mindst én forbindelse ifølge krav 1; og (b) et farmaceutisk acceptabelt bærestof.
  13. 13. Farmaceutisk sammensætning ifølge krav 12 endvidere omfattende et nød-middel udvalgt fra gruppen bestående af nicotinamid, nicotinsyre og nicotinamidmononucleotid (NMN) eller terapeutisk effektive mængder af en eller flere yderligere supplerende aktive midler, hvori det ene eller de flere yderligere supplerende aktive midler er udvalgt fra gruppen bestående af cytotoksisk middel, cisplatin, doxorubicin, taxotere, taxol, etoposid, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilonerne, tamoxifen, 5-fluoruracil, methoxtrexat, temozolomid, cyclophosphamid, SCH 66336, tipifarnib (Zarnestra®), R115777, L778,123, BMS 214662, Iressa®, Tarceva®, C225, GLEEVEC®, intron®, Peg-Intron®, aromatasekombinationer, ara-C, adriamycin, cytoxan, gemcitabin, Uracilsennep, Chlormethin, Ifosfamid, Melphalan, Chlorambucil, Pipobroman, Triethylenmelamin, Triethylenthiophosphoramin, Busulfan, Carmustin, Lomustin, Streptozocin, Dacarbazin, Floxuridin, Cytarabin, 6-Mercaptopurin, 6-Thioguanin, Fludarabinphosphat, leucovirin, oxaliplatin (ELOXATIN®), Pentostatin, Vinblastin, Vineristin, Vindesin, Bleomycin, Dactinomycin, Daunorubicin, Epirubicin, Idarubicin, Mithramycin™, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposid 17a-Ethinylestradiol, Diethylstilbestrol, Testosteron, Prednison, Fluoxymesteron, Dromostanolonpropionat, Testolacton, Megestrolacetat, Methylprednisolon, Methyltestosteron, Prednisolon, Triamcinolon, Chlortrianisen, Hydroxyprogesteron, Aminoglutethimid, Estramustin, Medroxyprogesteronacetat, Leuprolid, Flutamid, Toremifen, goserelin, Carboplatin, Hydroxyurea, Amsacrin, Procarbazin, Mitotan, Mitoxantron, Levamisol, Navelbine, Anastrazol, Letrazol, Capecitabin, Reloxafin, Droloxafin, Hexamethylmelamin, Avastin, herceptin, Bexxar, Velcade, Zevalin, Trisenox, Xeloda, Vinorelbin, Porflmer, Erbitux, Liposomal, Thiotepa, Altretamin, Melphalan, Trastuzumab, Lerozol, Fulvestrant, Exemestan, Ifosfomid, Rituximab, Campath, leueovorin og dexamethason, bicalutamid, carboplatin, chlorambucil, megestrol, valrubicin og NIASPAN®.
  14. 14. Forbindelse ifølge krav 1 eller et farmaceutisk acceptabelt salt deraf til anvendelse i behandlingen af en sygdom eller lidelse, som et subjekt lider af eller er diagnosticeret med, medieret af NAMPT-aktivitet, såsom en solid eller flydende tumor, ikke-småcellet lungecancer, leukæmi, lymfom, ovariecancer, gliom, brystcancer, uteruscancer, coloncancer, cervixcancer, lungecancer, prostatacancer, hudcancer, rhino-gastriske tumorer, colorectalcancer, CNS-cancer, blærecancer, pancreascancer, Hodgkins sygdom, rheumatoid arthritis, diabetes, aterosklerose, sepsis, aldring eller inflammation.
  15. 15. Forbindelse til anvendelse ifølge krav 14, hvori forbindelsen til anvendelse endvidere omfatter et nød-middel udvalgt fra gruppen bestående af nicotinamid, nicotinsyre og nicotinamidmononucleotid (NMN), eller mindst én forbindelse udvalgt fra gruppen bestående af: et cytotoksisk middel, cisplatin, doxorubicin, taxotere, taxol, etoposid, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilonerne, tamoxifen, 5-fluoruracil, methoxtrexat, temozolomid, cyclophosphamid, SCH 66336, tipifarnib (Zarnestra®), R115777, L778,123, BMS 214662, Iressa®, Tarceva®, C225, GLEEVEC®, intron®, Peg-Intron®, aromatasekombinationer, ara-C, adriamycin, cytoxan, gemcitabin, Uracilsennep, Chlormethin, Ifosfamid, Melphalan, Chlorambucil, Pipobroman, Triethylenmelamin, Triethylenthiophosphoramin, Busulfan, Carmustin, Lomustin, Streptozocin, Dacarbazin, Floxuridin, Cytarabin, 6-Mercaptopurin, 6-Thioguanin, Fludarabinphosphat, leucovirin, oxaliplatin (ELOXATIN®), Pentostatin, vineristin, Vindesin, Bleomycin, Dactinomycin, Daunorubicin, Epirubicin, Idarubicin, Mithramycin™, Deoxycoformycin, Mitomycin-C, L-Asparaginas, Teniposid 17a-Ethinylestradiol, Diethylstilbestrol, Testosteron, Prednison, Fluoxymesteron, Dromostanolonpropionat, Testolacton, Megestrolacetat, Methylprednisolon, Methyltestosteron, Prednisolon, Triamcinolon, Chlortrianisen, Hydroxyprogesteron, Aminoglutethimid, Estramustin, Medroxyprogesteronacetat, Leuprolid, Flutamid, Toremifen, goserelin, Carboplatin, Hydroxyurea, Amsacrin, Procarbazin, Mitotan, Mitoxantron, Levamisol, Navelbine, Anastrazol, Letrazol, Capecitabin, Reloxafin, Droloxafin, Hexamethylmelamin, Avastin, herceptin, Bexxar, Velcade, Zevalin, Trisenox, Xeloda, Vinorelbin, Porfimer, Erbitux, Liposomal, Thiotepa, Altretamin, Melphalan, Trastuzumab, Lerozol, Fulvestrant, Exemestan, Ifosfomid, Rituximab, Campath, leueovorin, dexamethason, bicalutamid, chlorambucil, megestrol, valrubicin, vinblastin og NIASPAN®.
DK13755811.0T 2012-03-02 2013-03-01 Amido-spirocycliske amid- og sulfonamidderivativer DK2820008T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261606291P 2012-03-02 2012-03-02
PCT/CN2013/000216 WO2013127269A1 (en) 2012-03-02 2013-03-01 Amido spirocyclic amide and sulfonamide derivatives

Publications (1)

Publication Number Publication Date
DK2820008T3 true DK2820008T3 (da) 2017-03-27

Family

ID=49081603

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13755811.0T DK2820008T3 (da) 2012-03-02 2013-03-01 Amido-spirocycliske amid- og sulfonamidderivativer

Country Status (19)

Country Link
US (4) US9822129B2 (da)
EP (1) EP2820008B1 (da)
JP (1) JP6404717B2 (da)
CN (1) CN104520290B (da)
AU (2) AU2013225533B2 (da)
CA (1) CA2865525C (da)
CY (1) CY1118869T1 (da)
DK (1) DK2820008T3 (da)
ES (1) ES2620668T3 (da)
HR (1) HRP20170411T1 (da)
HU (1) HUE032035T2 (da)
LT (1) LT2820008T (da)
PL (1) PL2820008T3 (da)
PT (1) PT2820008T (da)
RS (1) RS55807B1 (da)
SG (1) SG11201405056UA (da)
SI (1) SI2820008T1 (da)
SM (1) SMT201700290T1 (da)
WO (1) WO2013127269A1 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6038792B2 (ja) 2010-09-03 2016-12-07 フォーマ ティーエム， エルエルシー． 癌などの疾患の治療のためのｎａｍｐｔ阻害剤としての４−｛［（ピリジン−３−イル−メチル）アミノカルボニル］アミノ｝ベンゼン−スルホン誘導体
WO2012031197A1 (en) 2010-09-03 2012-03-08 Forma Therapeutics, Inc. Novel compounds and compositions for the inhibition of nampt
US9555039B2 (en) * 2011-05-09 2017-01-31 Forma Tm, Llc. Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)
EP2820018A4 (en) 2012-03-02 2015-09-02 Genentech Inc AMIDO-BENZYL-SULFON AND SULFOXIDE DERIVATIVES
DK2820008T3 (da) 2012-03-02 2017-03-27 Genentech Inc Amido-spirocycliske amid- og sulfonamidderivativer
CN106279143A (zh) * 2015-05-11 2017-01-04 天津国际生物医药联合研究院 噻唑杂环类化合物及其制备方法和应用
EP4074378A1 (en) * 2015-07-02 2022-10-19 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
KR102354784B1 (ko) 2015-08-05 2022-01-25 메트로 인터내셔널 바이오테크 엘엘씨 니코틴아미드 모노뉴클레오티드 유도체 및 그 용도
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
JP6790094B2 (ja) * 2015-11-12 2020-11-25 エーエフエーエスシーアイ，インコーポレイテッド イオンチャネル阻害化合物、医薬製剤および使用
EA201990043A1 (ru) 2016-06-16 2019-05-31 Янссен Сайенсиз Айрлэнд Анлимитед Компани Антибактериальные соединения
WO2018086703A1 (en) 2016-11-11 2018-05-17 Bayer Pharma Aktiengesellschaft Dihydropyridazinones substituted with phenylureas
EP3558312A4 (en) 2016-12-21 2021-01-13 Newsouth Innovations Pty Limited METHODS FOR INCREASING VASCULAR DENSITY
EP4417262A3 (en) 2017-03-01 2024-11-27 Janssen Sciences Ireland Unlimited Company Combination therapy
CN107163043A (zh) * 2017-06-16 2017-09-15 上海毕得医药科技有限公司 一种吡唑并[1,5‑a]吡啶‑3‑羧酸酯衍生物的合成方法
AU2018300980A1 (en) 2017-07-12 2020-01-02 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
EP3697781B1 (en) 2017-10-17 2023-06-07 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
ES3064093T3 (en) 2017-10-20 2026-04-22 Univ Vanderbilt Antagonists of the muscarinic acetylcholine receptor m4
WO2019126559A1 (en) 2017-12-20 2019-06-27 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
US11180521B2 (en) 2018-01-30 2021-11-23 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
WO2019178129A1 (en) 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
CN109369576B (zh) * 2018-09-19 2020-11-27 上海凌凯医药科技有限公司 一种合成3-甲基氧杂环丁烷-3-(4-硝基苯基)碳酸酯的方法
TWI767148B (zh) * 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
WO2020077071A1 (en) * 2018-10-10 2020-04-16 Forma Therapeutics, Inc. Inhibiting fatty acid synthase (fasn)
US10618927B1 (en) 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
PT4031547T (pt) 2019-09-18 2024-08-27 Takeda Pharmaceuticals Co Inibidores de calicreína plasmática e utilizações dos mesmos
US11370803B2 (en) 2019-09-18 2022-06-28 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
JP7736712B2 (ja) * 2020-05-06 2025-09-09 サイトキネティックス， インコーポレイテッド Ｎａｍｐｔモジュレーター
TWI904281B (zh) * 2020-11-13 2025-11-11 丹麥商Ｈ 朗德貝克公司 Magl抑制劑
BR112023024712A2 (pt) 2021-05-27 2024-02-15 Metro Int Biotech Llc Sólidos cristalinos de mononucleotídeo de ácido nicotínico e ésteres dos mesmos e métodos de fabricação e uso
CN117658900B (zh) * 2022-08-30 2025-11-21 南京药石科技股份有限公司 一种四氢萘啶类化合物的制备方法及其中间体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JP4710606B2 (ja) * 2003-04-18 2011-06-29 小野薬品工業株式会社 スピロピペリジン化合物およびその医薬用途
WO2007062093A2 (en) * 2005-11-22 2007-05-31 Incyte Corporation Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
US7910108B2 (en) * 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
US8450348B2 (en) 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
KR101273200B1 (ko) 2008-02-06 2013-06-17 펄마젠 쎄라퓨틱스 (시너지) 리미티드 화합물
US20100113465A1 (en) * 2008-10-30 2010-05-06 Pfizer Inc. 7-azaspiro[3.5]nonane-7-carboxamide compounds
FR2941696B1 (fr) * 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
FR2945531A1 (fr) 2009-05-12 2010-11-19 Sanofi Aventis Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique
WO2012031197A1 (en) 2010-09-03 2012-03-08 Forma Therapeutics, Inc. Novel compounds and compositions for the inhibition of nampt
RU2593759C2 (ru) 2010-09-03 2016-08-10 ФОРМА ТиЭм, ЭлЭлСИ Гуанидиновые соединения и композиции для ингибирования nampt
JP6038792B2 (ja) 2010-09-03 2016-12-07 フォーマ ティーエム， エルエルシー． 癌などの疾患の治療のためのｎａｍｐｔ阻害剤としての４−｛［（ピリジン−３−イル−メチル）アミノカルボニル］アミノ｝ベンゼン−スルホン誘導体
CA2834746A1 (en) 2011-05-04 2012-11-08 Forma Tm, Llc Novel compounds and compositions for the inhibition of nampt
US9555039B2 (en) 2011-05-09 2017-01-31 Forma Tm, Llc. Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)
DK2820008T3 (da) 2012-03-02 2017-03-27 Genentech Inc Amido-spirocycliske amid- og sulfonamidderivativer
WO2013127268A1 (en) 2012-03-02 2013-09-06 Genentech,Inc. Amido-benzyl sulfone and sulfonamide derivatives
CN104507936A (zh) 2012-03-02 2015-04-08 基因科技股份有限公司 吡啶基和嘧啶基亚砜和砜衍生物
WO2013130943A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Alkyl-and di-substituted amido-benzyl sulfonamide derivatives
EP2820018A4 (en) 2012-03-02 2015-09-02 Genentech Inc AMIDO-BENZYL-SULFON AND SULFOXIDE DERIVATIVES
WO2013130935A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Amido-benzyl sulfoxide derivatives

Also Published As

Publication number Publication date
PT2820008T (pt) 2017-05-05
US11485745B2 (en) 2022-11-01
CA2865525C (en) 2019-05-21
ES2620668T3 (es) 2017-06-29
US20180339998A1 (en) 2018-11-29
EP2820008B1 (en) 2016-12-14
AU2017254876A1 (en) 2017-11-23
CA2865525A1 (en) 2013-09-06
JP6404717B2 (ja) 2018-10-17
US20160002266A1 (en) 2016-01-07
HUE032035T2 (en) 2017-08-28
US10730889B2 (en) 2020-08-04
EP2820008A4 (en) 2015-08-26
SMT201700290T1 (it) 2017-07-18
HRP20170411T1 (hr) 2017-06-16
US20210171545A1 (en) 2021-06-10
PL2820008T4 (pl) 2018-04-30
CN104520290B (zh) 2020-10-09
WO2013127269A1 (en) 2013-09-06
RS55807B1 (sr) 2017-08-31
CY1118869T1 (el) 2018-01-10
US20170216262A1 (en) 2017-08-03
AU2013225533A1 (en) 2014-09-25
AU2013225533A8 (en) 2014-10-16
PL2820008T3 (pl) 2018-04-30
US9822129B2 (en) 2017-11-21
AU2013225533B2 (en) 2017-08-03
EP2820008A1 (en) 2015-01-07
SG11201405056UA (en) 2014-09-26
JP2015508786A (ja) 2015-03-23
LT2820008T (lt) 2017-06-12
SI2820008T1 (sl) 2017-06-30
CN104520290A (zh) 2015-04-15

Similar Documents

Publication Publication Date Title
US11485745B2 (en) Amido spirocyclic amide and sulfonamide derivatives
US11547701B2 (en) Compounds and compositions for the inhibition of NAMPT
EP2820017B1 (en) Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives
US10696692B2 (en) Amido-benzyl sulfone and sulfoxide derivates
WO2013130943A1 (en) Alkyl-and di-substituted amido-benzyl sulfonamide derivatives
AU2011367809A1 (en) Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)
WO2013127268A1 (en) Amido-benzyl sulfone and sulfonamide derivatives
WO2013130935A1 (en) Amido-benzyl sulfoxide derivatives